C oronary artery disease, myocardial infarction, and heart failure affect men and women differently, with women being largely protected before menopause (1) . Estrogens exert multiple protective effects in the cardiovascular system; these include antioxidant effects, antiinflammatory effects, and inhibition of cell proliferation, atherogenesis, and thrombosis (1) . In the cardiovascular system, estrogens exert both chronic (genomic) and rapid (nongenomic) effects through activation of target proteins, the estrogen receptors (2) . The classic estrogen receptors, ERa and ERb, are nuclear transcription factors that regulate gene expression (2) . In addition, membrane subpopulations of these receptors mediate rapid signaling events following estrogen stimulation (2) . Estrogen can also mediate its effects through the G proteinÀcoupled estrogen receptor (GPER), a membrane G protein-coupled receptor (GPCR) localized in the endoplasmic reticulum that mediates both the rapid and chronic effects meditated by estrogens (1) .
Cyclic guanosine monophosphate (cGMP) is an important intracellular messenger that contributes to coronary vasodilation, inhibition of cardiomyocyte proliferation, and inflammation, thus counteracting the development of cardiac hypertrophy and fibrosis (3). Soluble guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) in mammalian NO signaling, which leads to formation of cGMP as a second messenger (3) . In macrovascular and microvascular coronary endothelium, activation of membrane ERa and GPER induces the L-arginine/NOS3/NO/cGMP pathway (1, 2) . In addition to direct stimulation of cGMP formation through NO, estrogen may also prolong the half-life of cGMP by inhibiting phosphodiesterase 5 (PDE5), an enzyme responsible for the hydrolytic inactivation of cGMP (4) . In endothelial cells, PDE5 is localized to caveolae, where it breaks down cGMP but at the same time also stimulates NOS3 and NO bioactivity, thereby simultaneously contributing to both inactivation and synthesis of cGMP (3).
Heart failure is a clinical syndrome with a high prevalence and high mortality (5) . Heart failure with preserved ejection fraction (HFpEF) results from abnormal left ventricular diastolic function caused by multiple factors causing coronary microvascular dysfunction and subsequent development of cardiomyocyte hypertrophy and myocardial fibrosis;
predisposing factors include arterial hypertension, diabetes, obesity, and aging (5) . HFpEF is now the most common form of heart failure and a condition predominantly of post-menopausal women (5) . It is largely absent in pre-menopausal women but its prevalence rises after menopause, which indicates a protective role of endogenous estrogen (5) .
Drugs that stimulate cGMP production by directly activating sGC, as well as PDE5 inhibitors (6) The investigators also show that short-term stimulation of cardiomyocyte NOS activity by estrogen was completely abrogated in female animals that lacked non-nuclear ERa signaling. The findings are remarkable and provide new hints as to why heart failure pathophysiology and therapy may be different between men and women (5) . Importantly, these data confirm that hormone treatment with estrogen (17bestradiol, the biologically most important endogenous estrogen in pre-menopausal women) has remarkable beneficial effects on the failing female heart, and that estrogen treatment alone prevents many of the contractile and structural abnormalities (8) . The investigators report that estrogen largely normalized many of the measured parameters, whereas adding sildenafil to hormone therapy further improved systolic and diastolic function and reduced heart weight, cardiomyocyte hypertrophy, and myocardial fibrosis, which suggests additional therapeutic potential (7) .
Importantly, all these beneficial effects, as well as and HFpEF in particular, also specifically targeting women (5, 9) . Fukuma et al. (7) found that the interaction between estrogen and PDE5 was also present in male mice, albeit to a lesser extent, which suggests that the potentiation of PDE5 effects by estrogen might be independent of sex. Acute (non-nuclear) relaxation of human coronary arteries by estrogen has been previously demonstrated, with effects more pronounced in women than those in men (1) .
A question that is still unresolved is how precisely due to heart failure in women but not in men (9) . The investigators concluded that the study did not provide a definite mechanistic basis for this finding. While neprilysin inhibitors are known to degrade vasoactive peptides (e.g., endothelin-1), enkephalins, and adrenomedullin, they also-just like PDE5 inhibitors-increase the bioavailability of cGMP (10), a mechanism that in part could have contributed to the recent findings reported by McMurray et al. (9) . While in the PARAGON-HF trial postmenopausal women diagnosed with HFpEF with obesity and low BNP levels were not eligible to be included in the study (11) , they could still benefit from therapies that increase cGMP (11) . 
